The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Won, K.Y.; Kim, G.Y.; Kim, H.K.; Song, M.J.; Choi, S.I.; Bae, G.E.; Lim, S.J. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor. Pathol. Res. Pract. 2019, 215, 152639. [Google Scholar] [CrossRef]
- Ajani, J.A.; Lee, J.; Sano, T.; Janjigian, Y.Y.; Fan, D.; Song, S. Gastric adenocarcinoma. Nat. Rev. Dis. Primers 2017, 3, 17036. [Google Scholar] [CrossRef] [PubMed]
- Kayapinar, A.K.; Solakoglu, D.; Bas, K.; Oymaci, E.; Isbilen, B.; Calik, B.; Diniz, G. Relationship of prognostic factors in stomach cancer with helicobacter pylori: A retrospective study. Acta Gastroenterol. Belg. 2022, 84, 607–617. [Google Scholar]
- Usturalı Keskin, E.; Diniz, G.; Usturalı Mut, A.N.; Koca, Y.; Eryiğit Kokkoz, S.; Çakır, İ.E. Evaluation of the Relationship Between ARID1A Expression with Clinicopathologic Parameters in Gastric Carcinomas. J. Tepecik Educ. Res. Hosp. (JTERH) 2019, 29, 273–279. [Google Scholar] [CrossRef]
- Mishima, S.; Kawazoe, A.; Nakamura, Y.; Sasaki, A.; Kotani, D.; Kuboki, Y.; Bando, H.; Kojima, T.; Doi, T.; Ohtsu, A.; et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J. Immunother. Cancer 2019, 7, 24. [Google Scholar] [CrossRef]
- Santiago-Sánchez, G.S.; Pita-Grisanti, V.; Quiñones-Díaz, B.; Gumpper, K.; Cruz-Monserrate, Z.; Vivas-Mejía, P.E. Biological Functions and Therapeutic Potential of Lipocalin 2 in Cancer. Int. J. Mol. Sci. 2020, 21, 4365. [Google Scholar] [CrossRef]
- Crescenzi, E.; Leonardi, A.; Pacifico, F. NGAL as a Potential Target in Tumor Microenvironment. Int. J. Mol. Sci. 2021, 22, 12333. [Google Scholar] [CrossRef] [PubMed]
- Candido, S.; Maestro, R.; Polesel, J.; Catania, A.; Maira, F.; Signorelli, S.S.; McCubrey, J.A.; Libra, M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer. Oncotarget 2014, 5, 1576–1594. [Google Scholar] [CrossRef]
- Bolignano, D.; Donato, V.; Lacquaniti, A.; Fazio, M.R.; Bono, C.; Coppolino, G.; Buemi, M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. Cancer Lett. 2010, 288, 10–16. [Google Scholar] [CrossRef]
- Bauvois, B.; Susin, S.A. Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner? Cancers 2018, 10, 336. [Google Scholar] [CrossRef]
- Kahraman, D.S.; Diniz, G.; Sayhan, S.; Ersavas, S.; Ayaz, D.; Keskin, E.; Gulhan, I. Over expressions of neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in human uterine cervical neoplasms enhance tumor invasion. Eur. J. Gynaecol. Oncol. 2021, 42, 148–153. [Google Scholar]
- Ersavaş, S.; Diniz, G.; Yildirim, H.T.; Koca, Y.; Kahraman, D.S.; Ayaz, D.; Demirağ, B. Expression of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 in Wilms Tumor. Turk. Patoloji Derg. 2016, 32, 158–163. [Google Scholar] [CrossRef] [PubMed]
- Al-Bataineh, M.M.; Kinlough, C.L.; Mi, Z.; Jackson, E.K.; Mutchler, S.M.; Emlet, D.R.; Kellum, J.A.; Hughey, R.P. KIM-1-mediated anti-inflammatory activity is preserved by MUC1 induction in the proximal tubule during ischemia-reperfusion injury. Am. J. Physiol. Ren. Physiol. 2021, 321, F135–F148. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Brooks, C.R.; Xiao, S.; Sabbisetti, V.; Yeung, M.Y.; Hsiao, L.L.; Ichimura, T.; Kuchroo, V.; Bonventre, J.V. KIM-1-mediated phagocytosis reduces acute injury to the kidney. J. Clin. Investig. 2015, 125, 1620–1636. [Google Scholar] [CrossRef] [PubMed]
- Karmakova, T.A.; Sergeeva, N.S.; Kanukoev, K.Y.; Alekseev, B.Y.; Kaprin, A.D. Kidney Injury Molecule 1 (KIM-1): A Multifunctional Glycoprotein and Biological Marker. Sovrem. Tekhnologii Med. 2021, 13, 64–78. [Google Scholar] [CrossRef]
- Liu, L.; Song, Z.; Zhao, Y.; Li, C.; Wei, H.; Ma, J.; Du, Y. HAVCR1 expression might be a novel prognostic factor for gastric cancer. PLoS ONE 2018, 13, e0206423. [Google Scholar] [CrossRef]
- Zheng, X.; Xu, K.; Chen, L.; Zhou, Y.; Jiang, J. Prognostic value of TIM-1 expression in human non-small-cell lung cancer. J. Transl. Med. 2019, 17, 178. [Google Scholar] [CrossRef]
- Wang, Y.; Martin, T.A.; Jiang, W.G. HAVcR-1 expression in human colorectal cancer and its effects on colorectal cancer cells in vitro. Anticancer Res. 2013, 33, 207–214. [Google Scholar]
- Zhang, P.L.; Mashni, J.W.; Sabbisetti, V.S.; Schworer, C.M.; Wilson, G.D.; Wolforth, S.C.; Kernen, K.M.; Seifman, B.D.; Amin, M.B.; Geddes, T.J.; et al. Urine kidney injury molecule-1: A potential non-invasive biomarker for patients with renal cell carcinoma. Int. Urol. Nephrol. 2014, 46, 379–388. [Google Scholar] [CrossRef]
- Yang, J.; Bielenberg, D.R.; Rodig, S.J.; Doiron, R.; Clifton, M.C.; Kung, A.L.; Strong, R.K.; Zurakowski, D.; Moseset, M.A. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA 2009, 106, 3913–3918. [Google Scholar] [CrossRef]
- Monisha, J.; Padmavathi, G.; Bordoloi, D.; Roy, N.K.; Kunnumakkara, A.B. Neutrophil gelatinase-associated lipocalin (NGAL): A promising biomarker for cancer diagnosis and a potential target for cancer therapeutics. J. Cell Sci. Mol. Biol. 2014, 1, 106. [Google Scholar]
- Bauer, M.; Eickhoff, J.C.; Gould, M.N.; Mundhenke, C.; Maass, C.; Friedl, A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res. Treat. 2008, 108, 389–397. [Google Scholar] [CrossRef]
- Shimura, T.; Dagher, A.; Sachdev, M.; Ebi, M.; Yamada, T.; Yamada, T.; Joh, T.; Moses, M.A. Urinary ADAM12 and MMP-9/NGAL Complex Detect the Presence of Gastric Cancer. Cancer Prev. Res. 2015, 8, 240–248. [Google Scholar] [CrossRef]
- Che, K.; Han, W.; Zhang, M.; Niu, H. Role of neutrophil gelatinase-associated lipocalin in renal cell carcinoma. Oncol. Lett. 2021, 21, 148. [Google Scholar] [CrossRef] [PubMed]
- Xue, J.; Li, Y.; Yi, J.; Jiang, H. HAVCR1 Affects the MEK/ERK pathway in gastric adenocarcinomas and influences tumor progression and patient outcome. Gastroenterol. Res. Pract. 2019, 2019, 6746970. [Google Scholar] [CrossRef]
- Meier, J.K.; Schnetz, M.; Beck, S.; Schmid, T.; Dominguez, M.; Kalinovic, S.; Daiber, A.; Brüne, B.; Jung, M. Iron-Bound Lipocalin-2 Protects Renal Cell Carcinoma from Ferroptosis. Metabolites 2021, 11, 329. [Google Scholar] [CrossRef] [PubMed]
- Tsakogiannis, D.; Kalogera, E.; Zagouri, F.; Zografos, E.; Balalis, D.; Bletsa, G. Determination of FABP4, RBP4 and the MMP-9/NGAL complex in the serum of women with breast cancer. Oncol. Lett. 2021, 21, 85. [Google Scholar] [CrossRef] [PubMed]
- Wei, C.T.; Tsai, I.T.; Wu, C.C.; Hung, W.C.; Hsuan, C.F.; Yu, T.H.; Hsu, C.C.; Houng, J.Y.; Chung, F.M.; Lee, Y.J.; et al. Elevated plasma level of neutrophil gelatinase-associated lipocalin (NGAL) in patients with breast cancer. Int. J. Med. Sci. 2021, 18, 2689–2696. [Google Scholar] [CrossRef]
- Kurozumi, S.; Alsaeed, S.; Orah, N.; Miligy, I.M.; Joseph, C.; Aljohani, A.; Toss, M.S.; Fujii, T.; Shirabe, K.; Green, A.R.; et al. Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Res. Treat. 2020, 179, 557–564. [Google Scholar] [CrossRef]
n | % | ||
---|---|---|---|
Prognosis | Survived | 78 | 45.3 |
Exited | 94 | 54.7 | |
Tumor Location | Cardia/Proximal stomach | 37 | 21.5 |
Corpus/Distal stomach | 135 | 78.5 | |
Diagnosis | Intestinal-type | 115 | 66.9 |
Poorly adhesive/mixed | 57 | 33.1 | |
Pathologic T stage | pT1 | 12 | 7 |
pT2 | 22 | 12.8 | |
pT3 | 79 | 45.9 | |
pT4 | 59 | 34.3 | |
Metastasis to local lymph node(s) | Present | 138 | 80.3 |
Absent | 34 | 19.7 | |
Distant Metastasis | Liver | 16 | 9.3 |
Lungs | 12 | 6.9 | |
Peritoneum | 6 | 4.3 | |
Distant lymph nodes | 4 | 2.3 | |
Ovaries | 2 | 1.2 | |
Lymphovascular invasion | Present | 144 | 69.6 |
Perineural invasion | Present | 104 | 75.3 |
c-erbB2 expression (according to ASCO/CAP 2013 criteria) | Negative or 1+ | 120 | 69.7 |
2+ | 23 | 13.3 | |
3+/FISH positive | 29 | 16.9 | |
NGAL expression | Positive in tumor cell | 54 | 31.4 |
Positive in inflammatory cells | 23 | 13.4 | |
KIM-1 expression | Positive in tumor cell | 54 | 31.4 |
HER2 Positivity (*) | Absent N/% N = 143/83.1% | Present N/% N = 29/16.89% | p | |
---|---|---|---|---|
Gender | Male | 95/33.6 | 20/69 | 0.792 |
Female | 48/33.6 | 9/31 | ||
Tumor location | Proximal Stomach | 32/22.4 | 5/17.2 | 0.529 |
Corpus/Distal | 111/77.6 | 24/82.8 | ||
Histological Type | Intestinal-type | 96/67.1 | 19/65.5 | 0.177 |
Poorly adhesive/mixed | 47/32.9 | 10/34.5 | ||
Survival status | Deceased | 75/52.4 | 19/65.5 | 0.197 |
Lymph node metastases | Present | 116/81.2 | 22/75.9 | 0.410 |
Location of distant metastases | Liver | 11/8.2 | 5/18.9 | 0.037 |
Lung | 11/8.2 | 1/3.8 | ||
Peritoneum | 3/2.9 | 3/11.4 | ||
Ovary | 1/0.9 | 1/3.8 | ||
Lymphovascular invasion | Present | 125/87.5 | 19/65.5 | 0.179 |
Perineural invasion | Present | 90/62.9 | 14/48.2 | 0.007 |
Tumor stage | Early | 28/19.6 | 7/24.1 | 0.821 |
Late | 115/80.4 | 22/75.9 | ||
KIM1 expression | Present | 42/29.4 | 12/41.4 | 0.204 |
NGAL expression | Present | 46/32.2 | 9/27.6 | 0.628 |
For Quantitative data | Mean ± SD | Mean ± SD | p | |
Age (year) | 64.2 ± 12.7 | 63.2 ± 10.7 | 0.199 | |
Tumor diameter (cm) | 5.7 ± 3.2 | 6.6 ± 3.6 | 0.670 | |
Survival (months) | 25.6 ± 21.8 | 25.2 ± 24.3 | 0.197 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ayaz, D.; Diniz, G.; Pulular, A.G.; Solakoğlu Kahraman, D.; Varol, U.; Özkavruk Eliyatkın, N.; Sayhan, S.; Kayapınar, A.K. The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas. Curr. Oncol. 2025, 32, 190. https://doi.org/10.3390/curroncol32040190
Ayaz D, Diniz G, Pulular AG, Solakoğlu Kahraman D, Varol U, Özkavruk Eliyatkın N, Sayhan S, Kayapınar AK. The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas. Current Oncology. 2025; 32(4):190. https://doi.org/10.3390/curroncol32040190
Chicago/Turabian StyleAyaz, Duygu, Gülden Diniz, Ayşe Gül Pulular, Dudu Solakoğlu Kahraman, Umut Varol, Nuket Özkavruk Eliyatkın, Sevil Sayhan, and Ali Kemal Kayapınar. 2025. "The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas" Current Oncology 32, no. 4: 190. https://doi.org/10.3390/curroncol32040190
APA StyleAyaz, D., Diniz, G., Pulular, A. G., Solakoğlu Kahraman, D., Varol, U., Özkavruk Eliyatkın, N., Sayhan, S., & Kayapınar, A. K. (2025). The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas. Current Oncology, 32(4), 190. https://doi.org/10.3390/curroncol32040190